XML 47 R38.htm IDEA: XBRL DOCUMENT v3.23.3

Acquisitions (Asset Acquisitions) (Details) - USD ($) $ in Millions	1 Months Ended		9 Months Ended
	Aug. 31, 2023	Feb. 28, 2022	Sep. 30, 2022
Business Acquisition [Line Items]
Acquired IPR&D Expense			$ 333.8
DICE Therapeutics, Inc.
Business Acquisition [Line Items]
Acquired IPR&D Expense	$ 1,915.5
Versanis Bio, Inc.
Business Acquisition [Line Items]
Acquired IPR&D Expense	604.1
Emergence Therapeutics AG
Business Acquisition [Line Items]
Acquired IPR&D Expense	$ 406.5
BioMarin Pharmaceutical Inc.
Business Acquisition [Line Items]
Acquired IPR&D Expense		$ 110.0

X

- Definition

Payments for Asset Acquisitions

+ References

No definition available.

+ Details

Name:	lly_PaymentsForAssetAcquisitions
Namespace Prefix:	lly_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479907/805-20-50-5

+ Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_AssetAcquisitionAxis=lly_DICETherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AssetAcquisitionAxis=lly_VersanisBioIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AssetAcquisitionAxis=lly_EmergenceTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AssetAcquisitionAxis=lly_BioMarinPharmaceuticalIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: